期刊文献+

毛细管气相色谱法测定替格瑞洛中溶剂残留量 被引量:9

Determination of the solvent residue in ticagrelor by capillary gas chromatography
下载PDF
导出
摘要 目的建立毛细管气相色谱法测定替格瑞洛中7种有机溶剂残留量。方法采用DB-624色谱柱(60 m×0.53 mm,3.0μm),氮气作为载气,采用氢火焰离子化检测器检测,以N,N-二甲基甲酰胺为溶剂,以正己烷为内标物,检测替格瑞洛原料药中残留溶剂。结果二氯甲烷、甲醇、乙酸乙酯、四氢呋喃、正庚烷、乙醇和醋酸线性关系良好(r=0.999 0~0.999 6),平均回收率为99.0%~101.1%,定量限分别为4.23、3.00、2.50、1.44、1.00、2.00和5.01 mg·L^(-1)。结论建立的方法适用于替格瑞洛中7种残留溶剂的同时测定。 Objective To establish a capillary gas chromatography method for the determination of seven kinds of residual solvents in ticagrelor. Methods The samples were separated on DB-624 capillary column (60 m × 0. 53 mm × 3.0 μm ) and analyzed with FID detector. Nitrogen was used as carrier gas and N-hexane was used as the internal standard. Results There were good linear relationships in the experimental concentrations of dichloromethane, methanol, ethyl acetate, tetrahydrofuran, N-heptane, ethanol, acetic acid (r= 0. 999 0-0. 999 6). The average recoveries were ranged from 99. 0% to 101.1%. The limit of quantification were 3.00,2.00,4. 23,2. 50,1.44,1.00,5.01 mg· L^ -1 , separately. Conclusions The method is simple, sensitive, and accurate with good durability. It can be used for the determination of the seven residual organic solvents in ticagrelor.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2018年第2期125-130,共6页 Journal of Shenyang Pharmaceutical University
关键词 替格瑞洛 溶剂残留 毛细管气相色谱法 内标法 ticagrelor solvent residue capillary gas chromatography internal standard method
  • 相关文献

参考文献7

二级参考文献84

  • 1段东红,康玉英,刘世斌.毛细管气相色谱法检测多潘立酮中的残留溶剂[J].药物分析杂志,2006,26(4):541-542. 被引量:1
  • 2SEREBRUANY V L, MIDEI M G, MEILMAN H, et al. Platelet inhibition with prasugrel ( CS2747 ) com- pared with clopidogrel in patientsundergoing coronary stenting:the subset from the JUMBO study[ J]. Post- grad Med J,2006,82(968) :404 -410. 被引量:1
  • 3SUGIDACHI A, ASAI F, OGAWA T, et al. The in vi- vo pharmacologicalprofile of CS-747, a novel anti- platelet agent with platelet ADP receptor antagonist properties[ J ]. Br J Pharm aco1,2000,129 (7) : 1439 - 1446. 被引量:1
  • 4BRANDT J T, PAYNE C D, WIVIOTT S D, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation [ J ]. AmHeaaJ, 2007,153(1) :66. e9 -e16. 被引量:1
  • 5WALLENTIN L, VARENHORST C, JAMES S, et al. Prasugrel achievesgreater and faster P2Y12 receptor- mediated platelet inhibition than clopidogrel due to more efficient generation of its active me2tabolite in asp irin2treated patients with coronary artery disease EJ]. Eur Heart J,2007,29(1) :21 -30. 被引量:1
  • 6周海钧主译.药品注册的国际技术要求质量部分[M].北京:人民卫生出版社,2008:126-144. 被引量:1
  • 7World Health Organization. Top ten causes of death. Geneva.. World Health Organization 2011. Available from : http ://www. who. int/ me- diacentre/factsheets/fs310. 2008. pdf. Accessed December 14,2012. 被引量:1
  • 8Behan MW, Chew DP, Aylward PE. The role of antiplatelet therapy in the secondary prevention of coronary artery disease[J]. Curr Opin Cardiol, 2010, 25(4): 321-328. 被引量:1
  • 9Marczewski MM, Postula M, Kosior D. Novel an tiplatelet agents in the prevention of cardiovascular complications- focus on ticagrelor [J].Vase Health Risk Manag, 2010, 6:419-429. 被引量:1
  • 10Siller-Matula JM, Krumphuber J, Jilma B. Phar- macokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disea- ses[J]. BrJ Pharmacol, 2010, 159(3): 502-517. 被引量:1

共引文献62

同被引文献54

引证文献9

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部